(2016) compared weight loss medications (orlistat and phentermine/topiramate) to placebo in patients with HTN.[103] There were statistically significant improvements in SBP and DBP for individuals taking either orlistat (four studies with 2,058 patients) or phentermine/topiramate (one study with 1,305 patients) compared to placebo. The study that compared phentermine/topiramate to placebo found a high rate of low-severity side effects with use of phentermine/topiramate (85.4% for low-dose, 88.8% for high-dose) compared to placebo (77.3%), but a low rate of serious adverse events with use of phentermine/topiramate (3.4% for low-dose and 3.7% for high-dose) compared to placebo (4.2%).[103] The harms slightly outweighed the benefits. Evidence on other medications was not found and therefore not reviewed. As this is a Reviewed, New-added recommendation, the Work Group systematically reviewed evidence related to this recommendation identified in the evidence review conducted as part of this guideline update.[103] The confidence in the quality of the evidence was low due to risk of bias concerns and the small effect size. The harms slightly outweigh the benefits; there were gastrointestinal (GI) and musculoskeletal side effects with orlistat and relatively modest benefits. There is large variation in patient preferences regarding this medication because of the side effects. Patients may not want to take the medication, and there is the potential for taking the medication for life. Therefore, the Work Group decided upon a Neither for nor against recommendation. Recommendation 17. For the treatment of hypertension, there is insufficient evidence to suggest for or against bariatric surgery for patients with obesity and hypertension. (Neither for nor against | Reviewed, New-added) Discussion The Work Group also looked at the evidence for offering bariatric surgery for the treatment of HTN for patients with obesity and HTN. 